Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Penelope J. Bristow"'
Autor:
Louis Denis, Sanjeeva P. Reddy, Drew W. Rasco, Naomi B. Haas, Allison Janine Tyler, Niranjan Sathyanarayana Rao, Jorge A. Garcia, Penelope J. Bristow, Ulka N. Vaishampayan, Robert Dreicer, Allan J. Pantuck, Anthony W. Tolcher
Publikováno v:
Journal of Clinical Oncology. 35:240-240
240 Background: ASN001 is a novel, non-steroidal, potent inhibitor of CYP17 lyase. It selectively inhibits synthesis of testosterone over cortisol in the adrenals to avoid the need for co-administration of prednisone. ASN001 also exhibits high oral b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f904ff3a7b4e10cefbc43e8c1304f71e
https://doi.org/10.1200/jco.2017.35.6_suppl.240
https://doi.org/10.1200/jco.2017.35.6_suppl.240
Autor:
Venkatesan M Aranapakam, Sanjeeva Reddy, Roger A. Smith, Niranjan Rao, Amita Patnaik, Nitin K. Damle, Terry Plasse, Scott B Thompson, Drew W. Rasco, Kyriakos P. Papadopoulos, Penelope J. Bristow, Gupta Sandeep, Anthony W. Tolcher
Publikováno v:
Blood. 126:4009-4009
ASN002 is an orally bioavailable potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with low nM IC50 values in biochemical assays. It is currently under clinical evaluation in a phase I/II study for safety, tolerability, ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da9cfa39b0a3720c21f59a3fb15e5453
https://doi.org/10.1182/blood.v126.23.4009.4009
https://doi.org/10.1182/blood.v126.23.4009.4009